200 related articles for article (PubMed ID: 31983636)
1. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.
Godara A; Siddiqui NS; Lee LX; Toskic D; Fogaren T; Varga C; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):184-189. PubMed ID: 31983636
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
3. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab for the treatment of AL amyloidosis.
Sidiqi MH; Gertz MA
Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis.
Godara A; Palladini G
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1145-1159. PubMed ID: 33099430
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
Popkova T; Hajek R; Jelinek T
Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
Kaufman GP; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood; 2017 Aug; 130(7):900-902. PubMed ID: 28615223
[TBL] [Abstract][Full Text] [Related]
12. Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis.
Roccatello D; Fenoglio R; Baldovino S; Naretto C; Ferro M; Barreca A; Rossi D; Sciascia S
Autoimmun Rev; 2020 Sep; 19(9):102622. PubMed ID: 32663622
[TBL] [Abstract][Full Text] [Related]
13. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
[TBL] [Abstract][Full Text] [Related]
14. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Gertz MA; Landau H; Comenzo RL; Seldin D; Weiss B; Zonder J; Merlini G; Schönland S; Walling J; Kinney GG; Koller M; Schenk DB; Guthrie SD; Liedtke M
J Clin Oncol; 2016 Apr; 34(10):1097-103. PubMed ID: 26858336
[TBL] [Abstract][Full Text] [Related]
15. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
Milani P; Fazio F; Basset M; Berno T; Larocca A; Foli A; Riva M; Benigna F; Oliva S; Nuvolone M; Rodigari L; Petrucci MT; Merlini G; Palladini G
Am J Hematol; 2020 Aug; 95(8):900-905. PubMed ID: 32282971
[TBL] [Abstract][Full Text] [Related]
16. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
17. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
Parrondo RD; Majeed U; Sher T
Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
[TBL] [Abstract][Full Text] [Related]
18. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
[TBL] [Abstract][Full Text] [Related]
19. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
Roccatello D; Fenoglio R; Sciascia S; Naretto C; Rossi D; Ferro M; Barreca A; Malavasi F; Baldovino S
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531894
[TBL] [Abstract][Full Text] [Related]
20. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
[No Abstract] [Full Text] [Related]
[Next] [New Search]